BeStock  
Stocks › ARWR

Arrowhead Pharmaceuticals ARWR

US equityMarket cap rank #1888
$41.37 −$2.28 (-5.22%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $41.40 +0.07%
Open$43.15
Prev close$43.65
Day range$41.17 – $44.80
Volume3.91M
Market cap$5.85B
P/E (TTM)–
Dividend yield–

Ownership & positioning

Who holds it, who is betting against it, and where the big money is moving

Institutional ownership90.9%+2.83 pts vs. prior quarter
Institutions holding590-5 vs. prior quarter
Insider trades (recent)12 buys / 37 sellsNet selling
Short interest8.20% of floatDays to cover 8.5 · as of 30 Oct 2026
Short-sale volume share16.6%5-day average of daily volume

Short-sale volume as % of daily volume

11%16%21%26%Oct '26Oct '26Nov '26

Large-order net flow, last 20 sessions

Net of large-order buying minus selling, in USD. Over this window: −$8.00M (11 inflow days, 9 outflow days).

Net flow by order size, last 20 sessions

−$10.1MSuper+$2.1MBig+$20.6MMid+$8.7MSmall

Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.

The five largest holders on file together own 34.1% of shares outstanding.

Largest holders

  • BlackRock10.72%
  • Avoro Capital Advisors LLC8.04%
  • FMR6.62%
  • Vanguard Portfolio Management, LLC4.40%
  • State Street Global Advisors4.33%
  • Vanguard Capital Management, LLC4.33%
  • Norges Bank Investment Management2.76%
  • Christopher Anzalone2.69%

By investor type

  • Mutual Fund61.33%
  • Hedge Fund16.64%
  • Public Company5.37%
  • Individual/Insider3.32%
  • Sovereign Wealth Fund2.76%
  • Private Company1.74%
  • VC/PE Fund1.63%
  • Government Pension Fund1.00%

Reported short interest has risen from 6.52% to 8.20% of float over the last 6 biweekly reports (14 Aug 2026 to 30 Oct 2026).

Recent institutional activity

HolderTypePeriodShare changeNew stake
FMR Mutual Fund 2026/Q3 +1,317,882 6.6%
Morgan Stanley Public Company 2026/Q3 +750,314 1.3%
Morgan Stanley Investment Management Inc. Mutual Fund 2026/Q3 +750,314 1.3%
Artal Group S.A. VC/PE Fund 2026/Q3 +575,000 1.6%
State Street Global Advisors Mutual Fund 2026/Q3 +427,631 4.3%
BlackRock Mutual Fund 2026/Q3 +310,287 10.7%
Global Alpha Capital Management Ltd. Mutual Fund 2026/Q3 +259,374 0.2%
Davern Capital Partners, LP Hedge Fund 2026/Q3 +229,300 0.2%
Norges Bank Investment Management Sovereign Wealth Fund 2026/Q3 +2,192,072 2.8%
First Trust Advisors L.P. Mutual Fund 2026/Q3 +1,203,770 1.0%
Holocene Advisors, LP Hedge Fund 2026/Q3 +1,106,177 0.8%
FMR Mutual Fund 2026/Q3 +771,066 5.7%
Avoro Capital Advisors LLC Hedge Fund 2026/Q3 +655,556 8.0%
Dimensional Fund Advisors Mutual Fund 2026/Q3 +573,077 0.8%
Two Sigma Investments, LP Hedge Fund 2026/Q3 +544,809 0.4%

Institutional buy/sell activity by reporting period, largest moves first.

Insider transactions

DateInsiderTitleTransactionSharesPriceHeld after
17 Aug 2026 Adeoye Olukotun Independent Director Open Market Disposition -2,000 $86.96 31,600
17 Aug 2026 Michael Perry Independent Director Open Market Disposition -11,600 $87.30 103,640
14 Jun 2026 Matthew Cohen Director Other Acquisition +11,882 – 11,882
11 May 2026 Hongbo Lu Independent Director Open Market Disposition -2,970 $76.88 41,816
11 May 2026 Hongbo Lu Independent Director Intent to Sell (Form 144) -315,202 – –
22 Apr 2026 James Hamilton Chief Medical Officer and Head of R&D Automatic Disposition -10,000 $75.00 226,958
22 Apr 2026 James Hamilton Chief Medical Officer and Head of R&D Intent to Sell (Form 144) -10,000 – –
21 Apr 2026 Daniel Apel Chief Financial Officer Automatic Disposition -13,095 $71.92 12,905
21 Apr 2026 Daniel Apel Chief Financial Officer Intent to Sell (Form 144) -13,095 – –
4 Mar 2026 James Hamilton Chief Medical Officer and Head of R&D Automatic Disposition -10,000 $64.19 236,958
5 Jan 2026 Daniel Apel Chief Financial Officer Other Acquisition +75,000 – 175,000
5 Jan 2026 James Hamilton Chief Medical Officer and Head of R&D Other Acquisition +75,000 – 246,958
5 Jan 2026 Patrick O'Brien COO & Secretary Other Acquisition +75,000 – 208,750
5 Jan 2026 Patrick O'Brien COO & Secretary Other Disposition -2,500 – 263,658
4 Jan 2026 James Hamilton Chief Medical Officer and Head of R&D Automatic Disposition -40,164 $68.00 171,958
4 Jan 2026 James Hamilton Chief Medical Officer and Head of R&D Intent to Sell (Form 144) -40,164 $63.10 –
4 Jan 2026 Patrick O'Brien COO & Secretary Automatic Disposition -49,493 $68.00 341,158
1 Jan 2026 Christopher Anzalone Chairperson & CEO Automatic Disposition -13,187 $66.39 3,792,739
30 Dec 2025 Patrick O'Brien COO & Secretary Other Disposition -2,800 – 341,158
28 Dec 2025 Christopher Anzalone Chairperson & CEO Derivative Exercise and Sale -51,726 $69.33 3,805,926

From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.

Short interest, by report

Report dateShares short% of floatDays to cover
30 Oct 2026 11,583,518 8.2% 8.5
15 Oct 2026 10,959,276 7.8% 5.4
30 Sep 2026 10,760,463 7.6% 4.0
15 Sep 2026 9,272,290 6.6% 5.2
31 Aug 2026 9,426,449 6.7% 8.8
14 Aug 2026 9,207,426 6.5% 7.8

Discussion

No comments yet — be the first to weigh in on ARWR.

Sign in to join the discussion.

Scroll to Top